Genmab Corrects Executive Share Transaction, Reveals DKK 1,867.50 Pricing

Genmab A/S has issued a correction to a prior company announcement regarding managerial employee share transactions, fixing a critical data entry error that initially reported the share price as DKK 0.00. The corrected disclosure reveals that executives Jan van de Winkel and Anthony Pagano received vesting and net settlement of restricted stock units at a substantially higher valuation of DKK 1,867.50 per share. The correction, filed on March 2, 2026, highlights the importance of accurate reporting in executive compensation disclosures and underscores regulatory attention to insider trading documentation.

The Correction: From Error to Clarity

The original company announcement contained a significant clerical error that understated the economic value of restricted stock unit (RSU) transactions executed by two senior executives at the Danish biotechnology firm. The corrected filing provides the accurate share price of DKK 1,867.50, which represents the true market valuation at the time of vesting and net settlement.

Key details of the corrected disclosure include:

• Original error: Share price reported as DKK 0.00
• Corrected price: DKK 1,867.50 per share
• Affected executives: Jan van de Winkel and Anthony Pagano
• Original grant date: February 2023
• Transaction type: Vesting and net settlement of restricted stock units

The timing of this correction—occurring nearly three years after the initial RSU grant—is not unusual for equity compensation cycles. RSUs granted in February 2023 would typically follow a multi-year vesting schedule, with net settlement (where shares are issued and a portion withheld for taxes) occurring as vesting milestones are reached. The correction ensures that all stakeholders have accurate documentation of the shares issued and the value at which they were granted to company leadership.

Market Context: Biotech Compensation and Regulatory Scrutiny

Genmab A/S ($GMAB) operates in the highly competitive biopharmaceutical sector, where equity compensation remains a critical tool for attracting and retaining executive talent. The biotechnology industry is characterized by long development timelines, significant capital requirements, and intense competition for specialized expertise, making stock-based compensation particularly prevalent.

The correction takes on additional significance within the broader context of regulatory scrutiny surrounding insider transactions and executive compensation disclosure. Securities regulators across jurisdictions have intensified focus on the accuracy and timeliness of insider trading reports, particularly following high-profile corporate governance failures. For companies listed on multiple exchanges—as is common for major biotech firms—compliance with disclosure requirements across jurisdictions is essential.

Key market considerations:

• Biotech sector norms: Equity compensation typically comprises 30-50% of executive total compensation packages
• Regulatory environment: Enhanced scrutiny of insider transactions and compensation disclosures
• Shareholder attention: Investors increasingly demand transparency in executive pay alignment with company performance
• Share price context: The correction establishes DKK 1,867.50 as the relevant historical pricing for compensation analysis

The correction demonstrates proper corporate governance procedures—errors identified in insider transaction reporting are addressed through formal announcements ensuring all market participants have access to corrected information simultaneously.

Investor Implications: Transparency and Governance Quality

For Genmab shareholders, this correction carries several important implications. First, it confirms that the company maintains processes to identify and correct errors in regulatory filings, which speaks to governance quality. Second, the accurate pricing at DKK 1,867.50 provides clarity on the actual economic value transferred to executives, enabling shareholders to properly assess compensation levels and alignment with shareholder interests.

The correction also provides investors with accurate information for calculating the dilutive impact of equity compensation programs. In the biotechnology sector, where cash burn rates are substantial and equity is a primary currency for talent retention, understanding the true scope of share issuance to management is essential for valuation purposes.

Broader takeaways for investors monitoring Genmab:

• Governance quality: Proactive identification and correction of errors reflects internal controls
• Compensation transparency: Accurate share pricing enables proper assessment of executive pay practices
• Shareholder value: Corrected data supports informed decision-making on equity dilution
• Regulatory compliance: Demonstrates commitment to accurate insider transaction reporting

The executives receiving these RSUs—Jan van de Winkel (long-serving leadership at Genmab) and Anthony Pagano—occupy significant roles in the company's operations, making their compensation alignment with shareholder interests a material governance consideration. RSU grants with multi-year vesting schedules theoretically align executive and shareholder interests by creating incentives for sustained share price appreciation.

Forward Outlook

The correction to the March 2, 2026 company announcement represents a routine but important element of corporate governance administration. While data entry errors in regulatory filings are not uncommon, their prompt identification and public correction demonstrate the administrative rigor expected of major publicly traded companies. For Genmab investors, the corrected disclosure provides the accurate foundation necessary for assessing executive compensation practices and calculating the true economic impact of equity incentive programs on shareholder dilution and company value.

As the biotechnology sector continues to face pressure on valuations and investor scrutiny regarding capital allocation, the accuracy and transparency of executive compensation disclosures will remain an important governance metric monitored by institutional shareholders and proxy advisory firms.